{"nctId":"NCT00615030","briefTitle":"Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)","startDateStruct":{"date":"2008-01"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"count":96,"armGroups":[{"label":"Indacaterol Morning,Indacaterol Evening, Salmeterol","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Salmeterol","Drug: Placebo to Indacaterol","Drug: Placebo to Salmeterol"]},{"label":"Indacaterol Evening,Indacaterol Morning, Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Placebo to Indacaterol","Drug: Placebo to Salmeterol"]},{"label":"Salmeterol, Placebo, Indacaterol Morning","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Salmeterol","Drug: Placebo to Indacaterol","Drug: Placebo to Salmeterol"]},{"label":"Placebo, Salmeterol, Indacaterol Evening","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Salmeterol","Drug: Placebo to Indacaterol","Drug: Placebo to Salmeterol"]},{"label":"Indacaterol Morning, Placebo, Indacaterol Evening","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Placebo to Indacaterol","Drug: Placebo to Salmeterol"]},{"label":"Indacaterol Evening,Salmeterol, Indacaterol Morning","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Salmeterol","Drug: Placebo to Indacaterol","Drug: Placebo to Salmeterol"]},{"label":"Salmeterol, Indacaterol Evening, Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Salmeterol","Drug: Placebo to Indacaterol","Drug: Placebo to Salmeterol"]},{"label":"Placebo, Indacaterol Morning, Salmeterol","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Salmeterol","Drug: Placebo to Indacaterol","Drug: Placebo to Salmeterol"]},{"label":"Indacaterol Morning, Salmeterol, Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Salmeterol","Drug: Placebo to Indacaterol","Drug: Placebo to Salmeterol"]},{"label":"Indacaterol Evening, Placebo, Salmeterol","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Salmeterol","Drug: Placebo to Indacaterol","Drug: Placebo to Salmeterol"]},{"label":"Salmeterol, Indacaterol Morning, Indacaterol Evening","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Salmeterol","Drug: Placebo to Indacaterol","Drug: Placebo to Salmeterol"]},{"label":"Placebo, Indacaterol Evening, Indacaterol Morning","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Placebo to Indacaterol","Drug: Placebo to Salmeterol"]}],"interventions":[{"name":"Indacaterol","otherNames":["QAB149"]},{"name":"Salmeterol","otherNames":["Serevent®"]},{"name":"Placebo to Indacaterol","otherNames":[]},{"name":"Placebo to Salmeterol","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Male and female adults aged ≥ 40 years, who have signed an Informed Consent Form prior to initiation of any study-related procedure\n* Co-operative outpatients with a diagnosis of chronic obstructive pulmonary disease (COPD) (moderate to severe as classified by the Global initiative for chronic obstructive lung disease (GOLD) Guidelines, 2006) and:\n* Smoking history of at least 20 pack years\n* Post-bronchodilator FEV1 \\< 80% and ≥30% of the predicted normal value\n* Post-bronchodilator FEV1/forced vital capacity (FVC) \\< 70%\n\nExclusion criteria:\n\n* Pregnant or lactating females\n* Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to Visit 1 or during the run-in period\n* Patients requiring long term oxygen therapy (\\>15 h a day)\n* Patient who have had a respiratory tract infection 6 weeks prior to V2 (with further criteria)\n* Patients with concomitant pulmonary disease, pulmonary tuberculosis, or clinically significant bronchiectasis\n* Patients with history of asthma (with further criteria)\n* Patients with Type I or uncontrolled type II diabetes.\n* Patients who have clinically relevant laboratory abnormalities or a clinically significant abnormality\n* Any patient with active cancer or a history of cancer with less than 5 years disease free survival time\n* Patient with a history with long QT syndrome or whose QTc interval is prolonged\n* Patients with a hypersensitivity to any of the study drugs or drugs with similar chemical structure\n* Patients who have had treatment with an investigational drug (with further criteria)\n* Patients who have had live attenuated vaccination within 30 days prior to Visit 2, or during run-in period\n* Patients with known history of non compliance to medication\n* Patients unable to satisfactorily use a dry powder inhaler device or perform spirometry measurements\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Trough Forced Expiratory Volume in 1 Second (FEV1) Following 14 Days of Evening Dosing of Indacaterol Versus Placebo","description":"Trough FEV1 was assessed by performing spirometry measurements in the clinic for each treatment period. For the primary efficacy variable, trough FEV1 is the mean of two measurements taken at 23h 10 min and 23h 45 min post dose. The primary variable was analyzed using an analysis of covariance (ANCOVA) model with the (period) baseline FEV1 as covariate.\n\nThe (period) baseline FEV1 was defined as the value measured before the study drug administration in that treatment period.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.57","spread":"0.025"},{"groupId":"OG001","value":"1.37","spread":"0.025"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Assessed After 14 Days of Dosing for All Other Treatment Comparisons","description":"Trough FEV1 was assessed by performing spirometry measurements in the clinic for each treatment period. On the morning and evening of Day 15 trough FEV1 (i.e. mean of measurements performed 23 h 10 min and 23 h 45 min post-dose) were assessed. An analysis of covariance (ANCOVA) model was used with the (period) baseline FEV1 as covariate. The (period) baseline FEV1 was defined as the value measured before the study drug administration in that treatment period.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.56","spread":"0.025"},{"groupId":"OG001","value":"1.57","spread":"0.025"},{"groupId":"OG002","value":"1.51","spread":"0.025"},{"groupId":"OG003","value":"1.46","spread":"0.025"},{"groupId":"OG004","value":"1.36","spread":"0.025"},{"groupId":"OG005","value":"1.37","spread":"0.025"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":65},"commonTop":["Chronic obstructive pulmonary disease","Cough"]}}}